0001554795-18-000310.txt : 20181102 0001554795-18-000310.hdr.sgml : 20181102 20181102123754 ACCESSION NUMBER: 0001554795-18-000310 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181102 DATE AS OF CHANGE: 20181102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALTAIR INTERNATIONAL CORP. CENTRAL INDEX KEY: 0001570937 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 990385465 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-190235 FILM NUMBER: 181156219 BUSINESS ADDRESS: STREET 1: 2360 CORPORATE CIRCLE STE 400 CITY: HENDERSON STATE: NV ZIP: 89074-7722 BUSINESS PHONE: 702-988-8801 MAIL ADDRESS: STREET 1: 2360 CORPORATE CIRCLE STE 400 CITY: HENDERSON STATE: NV ZIP: 89074-7722 10-Q 1 atao1030form10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

Form 10-Q

 

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended SEPTEMBER 30, 2018

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

ALTAIR INTERNATIONAL CORP.

(Exact name of registrant as specified in its charter)

 

     
Nevada 333-190235 99-0385465
(State or other jurisdiction (Commission File Number) (IRS Employer
of Incorporation)   Identification Number)

 

 

 

6501 E. Greenway Pkwy #103-412

Scottsdale, AZ 85254

 

 

 

(Address of principal executive offices)

 

(760) 413-3927
(Registrant’s Telephone Number)

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑    No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Ruble 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☑
  Emerging growth company ☑

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☑    No ☐

 

As of October 30, 2018, there were 496,732,553 shares of the registrant’s $0.001 par value common stock issued and outstanding.

 

   

 

ALTAIR INTERNATIONAL CORP.

QUARTERLY REPORT

PERIOD ENDED SEPTEMBER 30, 2018

 

TABLE OF CONTENTS

 

      Page No.
    PART I - FINANCIAL INFORMATION  
       
Item 1.   Financial Statements F1 – F7
       
Item 2.   Management's Discussion and Analysis of Financial Condition and Results of Operations 10
       
Item 3.   Quantitative and Qualitative Disclosures About Market Risk 13
       
Item 4T.   Controls and Procedures 13
       
    PART II - OTHER INFORMATION  
       
Item 1.   Legal Proceedings 14
       
Item1A.   Risk Factors 14
       
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds 14
       
Item 3.   Defaults Upon Senior Securities 14
       
Item 4.   Mine Safety Disclosures 14
       
Item 5.   Other Information 14
       
Item 6.   Exhibits 14
       
    Signatures 15

 

 

Special Note Regarding Forward-Looking Statements

 

Information included in this Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Altair International Corp. (the “Company”), to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies and expectations of the Company, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that these projections included in these forward-looking statements will come to pass. Actual results of the Company could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company has no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

*Please note that throughout this Quarterly Report, and unless otherwise noted, the words "we," "our," "us," the "Company," or "ATAO" refers to Altair International Corp.

 

   

 

PART I - FINANCIAL INFORMATION

        

ITEM 1.FINANCIAL STATEMENTS

 

 

INDEX  F-1 
Balance Sheets as of September 30, 2018 (Unaudited) and March 31, 2018 (Audited)  F-2 
Statements of Operations for the Three and Six Months Ended September 30, 2018 and 2017 (Unaudited)  F-3 
Statements of Cash Flows for the Six Months Ended September 30, 2018 and 2017(Unaudited)  F-4 
Notes to the Financial Statements (Unaudited)  F-5 

 

 F-1 

 

 

ALTAIR INTERNATIONAL CORP.
BALANCE SHEETS
AS OF SEPTEMBER 30, 2018 AND MARCH 31, 2018
       
    

September 30,

2018

    

March 31,

2018

 
    (Unaudited)    (Audited) 
ASSETS          
Current Assets          
Cash  $17,885   $75 
Advances and deposits   3,067    —   
Total current assets   20,952    75 
           
Total assets  $20,952   $75 
           
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)          
Current Liabilities          
Accounts payable  $—     $17,948 
Loans payable   14,165    14,165 
Interest payable   473    1,354 
Promissory note due to related party   30,000    45,000 
Total current liabilities   44,638    78,467 
Total Liabilities   44,638    78,467 
           
Stockholders' Equity (Deficit)          
Common Stock, $0.001 par value, 2,000,000,000 shares authorized; 496,732,553 shares issued and outstanding at September 30, 2018 and 47,747,245 as at March 31, 2018   496,733    47,747 
Additional paid-in-capital   350,693    432,052 
Common Stock subscribed   —      267,627 
Accumulated deficit   (871,112)   (825,818)
Total stockholders' equity (deficit)   (23,686)   (78,392)
Total liabilities and stockholders's equity (deficit)  $20,952   $75 
           
           
The accompanying notes are an integral part of these financial statements

 

 F-2 

 

 

ALTAIR INTERNATIONAL CORP.
STATEMENTS OF OPERATIONS
             
   Three Month Period Ended September 30, 2018  Three Month Period Ended September 30, 2017  Six Month Period Ended September 30, 2018  Six Month Period Ended September 30, 2017
   (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited)
Expenses            
Total General and Administrative expenses  $20,509   $1,383   $44,147   $1,698 
Gain on conversion of debt   —      (63,417)   —      (63,417)
Change in the fair value of derivative liabilities   —      (55,238)   —      (244,717)
Interest expense   473    67,182    1,147    135,655 
                     
Loss (earnings) before income taxes   20,982    (50,090)   45,294    (170,781)
Income taxes   —      —      —      —   
Net loss (earnings)  $20,982   $(50,090)  $45,294   $(170,781)
                     
Loss (earnings) per share - Basic and diluted  $0.0002   $(0.0016)  $0.0013   $(0.0053)
Weighted Average Shares - Basic and diluted   92,867,280    31,957,000    34,418,928    31,957,000 
                     
                     
The accompanying notes are an integral part of these financial statements.

 

 F-3 

 

 

ALTAIR INTERNATIONAL CORP.
STATEMENTS OF CASH FLOWS
       
    

Six Month Period Ended

September 30, 2018

    

Six Month Period Ended

September 30, 2017

 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net income (loss)  $(45,294)  $170,781 
Adjustments to reconcile net loss to net cash used in operating activities:          
Changes in:          
Advances and deposits   (3,067)     
Accounts payable   (17,948)   (5,675)
Interest payable   (881)   11,368 
Fair value of derivative liabilities   —      (244,717)
Gain on conversion of debt   —      (63,417)
Debt discount   —      124,287 
    (67,190)   (7,373)
           
CASH FLOWS FROM INVESTING ACTIVITIES   —      —   
           
CASH FLOW FROM FINANCING ACTIVITIES          
Proceeds from common stock subscriptions   100,000    —   
Payments on Promissory Note due to related party   (15,000)   —   
    85,000    —   
           
NET INCREASE IN CASH AND CASH EQUIVALENTS   17,810    (7,373)
           
CASH AND CASH EQUIVALENTS          
Beginning of period   75    7,523 
End of period  $17,885   $150 
           
Supplemental disclosures of cash flow information          
Taxes paid  $—     $—   
Interest paid  $—     $—   
           
Non-cash Financing and Investing Activities          
Conversion of Promissory Notes to Third Parties  $—      332,213 
Conversion of Promissory Notes to Related Party   —      39,373 
Accrued Interest on Promissory Notes   —      23,943 
   $—      395,529 
           
Interest expense - debt discount in period   —      124,287 
           
Reduction of derivative liability in period   —      252,896 
Reduction of derivative liability - mark          
to market on conversion of Promissory Notes   —      55,239 
   —      308,135 
 
 
The accompanying notes are an integral part of these financial statements.

 

 F-4 

 

ALTAIR INTERNATIONAL CORP.

Notes to the Financial Statements

September 30, 2018

(Unaudited)

 

 

The results for the six months ended September 30, 2018 are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10K for the year ended March 31, 2018, filed with the Securities and Exchange Commission.

 

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2018 and for the related periods presented have been made.

 

 

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

 

Organization and Description of Business

 

ALTAIR INTERNATIONAL CORP. (the “Company”) was incorporated under the laws of the State of Nevada on December 20, 2012. The Company’s physical address is 18934 N 92nd Way, Scottsdale, AZ 85255. The Company is in the development stage as defined under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915-205 "Development-Stage Entities.”

 

The Company is currently engaged in identifying and assessing new business opportunities.

 

On November 11, 2014, the Company entered into a strategic alliance with Cure Pharmaceutical Corporation (“CURE”), a California company engaged in the development of oral thin film (“OTF”) for the delivery of nutraceutical, over-the-counter and prescription products. This alliance was initially comprised of an Exclusive License and Distribution Agreement for CURE’s Sildenafil Products in defined territories, a joint venture agreement for the procurement of equipment specific for oral thin film products and further joint ventures and other business relationships for the purpose of completing the development and marketing of additional products. Altair advanced $560,000 to CURE in this regard.

 

In September, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products. In its place, the Company and CURE entered into an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products. The Company has been unable to generate any sales of these products due to a lack of working capital and the human resources required to introduce the products to market. The Company wrote off its $560,000 investment in the agreement in the financial statements for the year ended March 31, 2017.

 

The Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described above.

 

Since inception (December 20, 2012) through September 30, 2018, the Company has not generated any revenue and has accumulated losses of $871,112.

 

In management’s opinion all adjustments necessary for a fair statement of the results for the interim periods have been made, and that all adjustments have been made to maintain the books in accordance with GAAP. Furthermore, sufficient disclosures have been made in order to ensure that the interim financial statements will not be misleading.

 

NOTE 2 - GOING CONCERN

 

The financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.  The Company has incurred losses since inception resulting in an accumulated deficit of $871,112 as of September 30, 2018 and further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern.  The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of common stock. 

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six month periods ending September 30, 2018 and 2017 and year ending March 31, 2018.

 

Cash and Cash Equivalents

 

For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At September 30, 2018 the Company's bank deposits did not exceed the insured amounts.

 

 F-5 

 

Basic and Diluted Income (Loss) Per Share

 

The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period.  Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.

 

Income Taxes

 

The Company follows the liability method of accounting for income taxes.  Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences).  The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Fair Value of Financial Instruments

 

FASB ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

 

These tiers include:

 

Level 1: defined as observable inputs such as quoted prices in active markets;

 

Level 2:  defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

Level 3:  defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Reclassifications

 

Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the six month period September 30, 2018.

 

NOTE 4 – LOANS PAYABLE

 

During the fiscal year ended March 31, 2016, the Company obtained a loan from a third party in the amount of $4,175. A further $9,990 was loaned to the Company in the six months ended September 30, 2016. This loan is non-interest bearing, is unsecured and has no fixed terms of repayment.

 

NOTE 5 – LOAN ADVANCES

 

On April 10, 2018, the Company entered into a non-binding Memorandum of Understanding with Dr. Judy Pham wherein Dr. Pham agreed to provide up to $100,000 in equity financing to assist with a corporate reorganization including bringing the Company current in its regulatory filings. On September 26, 2018 Dr. Phan completed her commitment to advance the Company $100,000. On September 27, 2018, the Company entered into a Securities Purchase Agreement with Dr. Judy Pham whereby she acquired 422,222,670 common shares of the Company for the $100,000 in loan advances.

 

 F-6 

 

NOTE 6 – COMMON STOCK

 

On August 24, 2018, the Company increased its authorized share capital from 75,000,000 common shares to 2,000,000 common shares with a par value of $0.001.

 

The Company had 47,747,245 common shares issued and outstanding at March 31, 2018.

 

In addition, the Company had received share subscriptions and Promissory Note conversion notices for the issuance of an additional 26,762,638 common shares. These shares were issued to the subscribers on April 19, 2018.

 

On September 27, 2018, the Company entered into a Securities Purchase Agreement with Dr. Judy Pham whereby she acquired 422,222,670 common shares of the Company for $100,000 in cash advances.

 

The Company had 496,732,553 common shares issued and outstanding at September 30, 2018.

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

From inception through September 29, 2016, the Directors loaned the Company $84,374 net of repayments to pay for incorporation costs, general and administrative expenses and professional fees and the acquisition of sales and distribution licenses and advances to Cure Pharmaceutical.  On September 29, 2016, this amount was settled through the issuance of a convertible promissory note. On September 29, 2017, the Director converted $39,373 of principal and $5,062 accrued interest on the promissory note into 4,443,565 shares of common stock. A new non-convertible unsecured, 6% promissory note for the remaining principal balance of $45,000 was issued. The new note matures in eighteen months. On September 29, 2018, the Company made a partial repayment of $15,000 on this note.

 

On September 29, 2016, the Company entered into a consulting agreement with the Company’s sole officer and director for the provision of management and financial services. This agreement called for a one time payment of $10,000 on signing of the agreement, and payments of $5,000 per month for six months, terminating on March 30, 2017. In addition, an amount of $5,000 for services provided in September, 2016 was payable on either the termination of the contract or completion of a minimum $500,000 financing. As of September 30, 2018, all amounts due to the consultant including $2,500 in late payment fees pursuant to this contract ($47,500) had been paid.

 

On April 10, 2018, the Company agreed to pay the sole officer and director of the company $2,500 per month for a period of 4 months for the provision of management and financial services. On September 1, 2018, the Company agreed to extend this contract on a month-to-month basis at the existing rate of $2,500 per month. $12,500 has been paid to September 30, 2018 pursuant to this agreement.

 

NOTE 8 – SUBSEQUENT EVENTS

 

In accordance with ASC 855-10, the Company has analyzed its operations from September 30, 2018 to October 30, 2018 and has determined that it has no material subsequent events to disclose in these financial statements.

 

END OF NOTES TO FINANCIAL STATEMENTS

 

 F-7 

 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF OPERATION

 

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. You should read this report completely and with the understanding that actual future results may be materially different from what we expect. The forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

Our Business

 

Altair International Corp. (“Altair”) is a development stage company that was incorporated in Nevada on December 20, 2012.

 

On November 11, 2014, the Company entered into a strategic alliance with Cure Pharmaceutical Corporation (“CURE”), a California company engaged in the development of oral thin film (“OTF”) for the delivery of nutraceutical, over-the-counter and prescription products. This alliance was initially comprised of an Exclusive License and Distribution Agreement for CURE’s Sildenafil Products in defined territories, a joint venture agreement for the procurement of equipment specific for oral thin film products and further joint ventures and other business relationships for the purpose of completing the development and marketing of additional products. Altair advanced $560,000 to CURE in this regard.

 

In September, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products. In its place, the Company and CURE entered into an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products. The Company has been unable to generate any sales of these products due to a lack of working capital and the human resources required to introduce the products to market, and accordingly wrote off its $560,000 investment in the agreement in the financial statements for the year ended March 31, 2017.

 

The Company is currently engaged in identifying and assessing new business opportunities.

 

The Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described above.

 

RESULTS OF OPERATIONS

 

We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

 

We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional funds through, among other things, the sale of equity or debt securities, although no assurance can be given that such funds will be available.

 

Working Capital

 

  

As of

September 30, 2018

 

As of

March 31, 2018

Total Current Assets  $20,952    75 
Total Current Liabilities   44,638    78,467 
Working Capital (Deficit)  $(23,686)   (78,392)

 

Cash Flows

 

  

Six Months Ended

September 30, 2018

 

Six Months Ended

September 30, 2017

Cash Flows from (used in) Operating Activities  $(67,190)   (7,373)
Cash Flow from (used in) Investing Activities   —      —   
Cash Flows from (used in) Financing Activities   85,000    —   
Net Increase (decrease) in Cash during period  $17,810    (7,373)

 

Operating Revenues

 

During the six month period ending September 30, 2018, the Company did not record any revenues. During fiscal year ended March 31, 2018, the Company did not generate any revenue.

 

 10 

 

Operating Expenses and Net Loss

 

Operating expenses during the three month period ended September 30, 2018 were $20,509 consisting of travel and general and administrative expenses which includes corporate overhead and financial and contracted services, as compared to $1,383 for the three month period ended September 30, 2017.

 

Interest expense (recovery) for the three month period ended September 30, 2018 was $473 as compared to $67,182 for the three month period ended September 30, 2017. The fair value of derivative liabilities decreased by $Nil in the three month period ended September 30, 2018 as compared to an increase of $55,238 for the three month period ended September 30, 2017. A $63,417 gain on conversion of debt was recorded in the three month period ended September 30, 2017.

 

Net loss for the three month period ended September 30, 2018 was $20,982, in comparison to net earnings of $50,090 for the three months ended September 30, 2017.

 

Liquidity and Capital Resources

 

As at September 30, 2018, the Company’s current assets were $20,952 and at March 31, 2018 were $75. As at September 30, 2018, the Company had total liabilities of $44,638, consisting of a $30,000 Promissory Note payable to a related party, $14,165 in loans payable to a third party and $473 in interest payable.  As at September 30, 2018, the Company had a working capital deficit of $23,686.

 

As at September 30, 2017, the Company’s current assets were $150 and at March 31, 2017 were $7,523. As at September 30, 2017, the Company had total liabilities of $75,080, consisting of $15,915 in accounts payable, a $45,000 Promissory Note payable to a related party and $14,165 in loans payable to a third party.  As at September 30, 2017, the Company had a working capital deficit of $74,930.

 

Cash flow from/used in Operating Activities

 

We have not generated positive cash flows from operating activities. During the six month period ended September 30, 2018, the Company used $67,190 of cash for operating activities. For the six month period ended September 30, 2017 the Company used $7,373 of cash for operating activities.

 

Cash flow from Financing Activities

 

We have financed our operations primarily from either advancements or the issuance of equity and debt instruments. During the six month period ended September 30, 2018, the Company received $85,000 of cash net of loan repayments from financing activities. For the six month period ended September 30, 2017 the Company received $Nil of cash from financing activities.

 

Going Concern

 

We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive acquisitions and activities. For these reasons, our auditors stated in their report on our audited financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing. The financial statements have been prepared "assuming that we will continue as a going concern," which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

 

 11 

 

Future Financings

 

We will continue to rely on equity sales of our common shares or debt financing arrangements in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing to fund our operations and other activities.

 

Critical Accounting Policies

 

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

 

Contractual Obligations

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

Recently Issued Accounting Pronouncements

 

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

 12 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

ITEM 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures, as required by Exchange Act Rule 13a-15. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective as of September 30, 2018 to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate control over financial reporting (as defined in Rule 13a-15(f) promulgated under the Exchange Act. Our management assessed the effectiveness of our internal control over financial reporting as of September 30, 2018. Our management has concluded that, as of September 30, 2018, our internal control over financial reporting is effective.

 

Changes in Internal Control and Financial Reporting

 

There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of September 30, 2018, that occurred during our second fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.  

 

This quarterly report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting.  Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this quarterly report.

 

 13 

 

PART II—OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

ITEM 1A. RISK FACTORS

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Quarterly Issuances:

 

None

 

Subsequent Issuances:

 

None

 

ITEM 3. Defaults Upon Senior Securities

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

Exhibit

Number

Description of Exhibit Filing
3.01 Articles of Incorporation Filed with the SEC on July 29, 2013 as part of our Registration Statement on Form S-1.
3.02 Bylaws Filed with the SEC on July 29, 2013 as part of our Registration Statement on Form S-1.
31.01 CEO and CFO Certification Pursuant to Rule 13a-14 Filed herewith.
32.01 CEO and CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act Filed herewith.
     
101.INS* XBRL Instance Document Filed herewith.
101.SCH* XBRL Taxonomy Extension Schema Document Filed herewith.
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document Filed herewith.
101.LAB* XBRL Taxonomy Extension Labels Linkbase Document Filed herewith.
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document Filed herewith.
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document Filed herewith.

 

(i)*Pursuant to Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

 

 14 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

ALTAIR INTERNATIONAL CORP.

 

 

Dated: November 2, 2018 /s/ Alan M. Smith
  By: Alan M. Smith
  Its: President, CEO, CFO, Secretary, Treasurer and Director

 

 

 

Pursuant to the requirement of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the Company and in the capacities and on the dates indicated:

 

 

Dated: November 2, 2018 /s/ Alan M. Smith
  By: Alan M. Smith
  Its: President, CEO, CFO, Secretary, Treasurer and Director

 

 

15

EX-31.1 2 atao1030form10qexh31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

 

CERTIFICATION

 

I, Alan M. Smith, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Altair International Corp. (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

 

Date: November 2, 2018

 

    /s/ Alan M. Smith
    Alan M. Smith
   

Chief Executive Officer

EX-31.2 3 atao1030form10qexh31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

 

CERTIFICATION

 

I, Alan M. Smith, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Altair International Corp. (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

 

Date: November 2, 2018

 

    /s/ Alan M. Smith
    Alan M. Smith
    Chief Financial Officer

EX-32.1 4 atao1030form10qexh32_1.htm EXHIBIT 32.1

 EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Altair International Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan M. Smith, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: November 2, 2018   /s/ Alan M. Smith
    Alan M. Smith
    Chief Executive Officer
     

 

EX-32.2 5 atao1030form10qexh32_2.htm EXHIBIT 32.2

 EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Altair International Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan M. Smith, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: November 2, 2018   /s/ Alan M. Smith
    Alan M. Smith
    Chief Financial Officer
     

EX-101.INS 6 atao-20180930.xml XBRL INSTANCE FILE 0001570937 2018-04-01 2018-09-30 0001570937 2018-10-30 0001570937 2018-09-30 0001570937 2018-03-31 0001570937 2017-04-01 2017-09-30 0001570937 2014-04-01 2015-03-31 0001570937 2012-12-20 2016-09-29 0001570937 2016-09-29 0001570937 2016-10-01 2017-03-30 0001570937 2016-09-01 2016-09-30 0001570937 2017-09-30 0001570937 2016-04-01 2017-03-31 0001570937 2015-04-01 2016-03-31 0001570937 2016-04-01 2016-09-30 0001570937 2017-03-31 0001570937 2018-07-01 2018-09-30 0001570937 2017-07-01 2017-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ALTAIR INTERNATIONAL CORP. 0001570937 10-Q 2018-09-30 false --03-31 Yes Non-accelerated Filer Q2 2019 496732553 0.001 0.001 2000000000 75000000 496732553 47747245 496732553 47747245 <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Organization and Description of Business</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ALTAIR INTERNATIONAL CORP. (the &#8220;Company&#8221;) was incorporated under the laws of the State of Nevada on December 20, 2012. The Company&#8217;s physical address is 18934 N 92<sup>nd</sup> Way, Scottsdale, AZ 85255. The Company is in the development stage as defined under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 915-205 &#34;Development-Stage Entities.&#8221;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company is currently engaged in identifying and assessing new business opportunities.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On November 11, 2014, the Company entered into a strategic alliance with Cure Pharmaceutical Corporation (&#8220;CURE&#8221;), a California company engaged in the development of oral thin film (&#8220;OTF&#8221;) for the delivery of nutraceutical, over-the-counter and prescription products. This alliance was initially comprised of an Exclusive License and Distribution Agreement for CURE&#8217;s Sildenafil Products in defined territories, a joint venture agreement for the procurement of equipment specific for oral thin film products and further joint ventures and other business relationships for the purpose of completing the development and marketing of additional products. Altair advanced $560,000 to CURE in this regard.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In September, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE&#8217;s Sildenafil Products. In its place, the Company and CURE entered into an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products. The Company has been unable to generate any sales of these products due to a lack of working capital and the human resources required to introduce the products to market. The Company wrote off its $560,000 investment in the agreement in the financial statements for the year ended March 31, 2017.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described above.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since inception (December 20, 2012) through September 30, 2018, the Company has not generated any revenue and has accumulated losses of $871,112.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">In management&#8217;s opinion all adjustments necessary for a fair statement of the results for the interim periods have been made, and that all adjustments have been made to maintain the books in accordance with GAAP. Furthermore, sufficient disclosures have been made in order to ensure that the interim financial statements will not be misleading.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Basis of Presentation</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six month periods ending September 30, 2018 and 2017 and year ending March 31, 2018.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Cash and Cash Equivalents</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At September 30, 2018 the Company's bank deposits did not exceed the insured amounts.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Basic and Diluted Income (Loss) Per Share</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company computes loss per share in accordance with &#8220;ASC-260&#8221;, &#8220;Earnings per Share&#8221; which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. &#160;Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Income Taxes</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company follows the liability method of accounting for income taxes. &#160;Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). &#160;The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair Value of Financial Instruments</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">FASB ASC 820 &#34;Fair Value Measurements and Disclosures&#34; establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These tiers include:</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 1: defined as observable inputs such as quoted prices in active markets;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 2: &#160;defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 3: &#160;defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Use of Estimates</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period.&#160;&#160;Actual results could differ from those estimates.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Reclassifications</u></font></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the six month period September 30, 2018.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Basis of Presentation</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six month periods ending September 30, 2018 and 2017 and year ending March 31, 2018.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Cash and Cash Equivalents</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At September 30, 2018 the Company's bank deposits did not exceed the insured amounts.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Basic and Diluted Income (Loss) Per Share</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company computes loss per share in accordance with &#8220;ASC-260&#8221;, &#8220;Earnings per Share&#8221; which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. &#160;Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Income Taxes</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company follows the liability method of accounting for income taxes. &#160;Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). &#160;The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair Value of Financial Instruments</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">FASB ASC 820 &#34;Fair Value Measurements and Disclosures&#34; establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These tiers include:</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 1: defined as observable inputs such as quoted prices in active markets;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 2: &#160;defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 3: &#160;defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Use of Estimates</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period.&#160;&#160;Actual results could differ from those estimates.</font></p> 250000 <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>NOTE 6 &#8211; COMMON STOCK</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 24, 2018, the Company increased its authorized share capital from 75,000,000 common shares to 2,000,000 common shares with a par value of $0.001.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company had 47,747,245 common shares issued and outstanding at March 31, 2018.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In addition, the Company had received share subscriptions and Promissory Note conversion notices for the issuance of an additional 26,762,638 common shares. These shares were issued to the subscribers on April 19, 2018.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On September 27, 2018, the Company entered into a Securities Purchase Agreement with Dr. Judy Pham whereby she acquired 422,222,670 common shares of the Company for $100,000 in cash advances.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company had 496,732,553 common shares issued and outstanding at September 30, 2018.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>NOTE 7 &#8211; RELATED PARTY TRANSACTIONS</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">From inception through September 29, 2016, the Directors loaned the Company $84,374 net of repayments to pay for incorporation costs, general and administrative expenses and professional fees and the acquisition of sales and distribution licenses and advances to Cure Pharmaceutical. &#160;On September 29, 2016, this amount was settled through the issuance of a convertible promissory note. On September 29, 2017, the Director converted $39,373 of principal and $5,062 accrued interest on the promissory note into 4,443,565 shares of common stock. A new non-convertible unsecured, 6% promissory note for the remaining principal balance of $45,000 was issued. The new note matures in eighteen months. On September 29, 2018, the Company made a partial repayment of $15,000 on this note.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On September 29, 2016, the Company entered into a consulting agreement with the Company&#8217;s sole officer and director for the provision of management and financial services. This agreement called for a one time payment of $10,000 on signing of the agreement, and payments of $5,000 per month for six months, terminating on March 30, 2017. In addition, an amount of $5,000 for services provided in September, 2016 was payable on either the termination of the contract or completion of a minimum $500,000 financing. As of September 30, 2018, all amounts due to the consultant including $2,500 in late payment fees pursuant to this contract ($47,500) had been paid.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 10, 2018, the Company agreed to pay the sole officer and director of the company $2,500 per month for a period of 4 months for the provision of management and financial services. On September 1, 2018, the Company agreed to extend this contract on a month-to-month basis at the existing rate of $2,500 per month. $12,500 has been paid to September 30, 2018 pursuant to this agreement.</font></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>NOTE 8 &#8211; SUBSEQUENT EVENTS</u></font></p> <p style="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 8.35pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In accordance with ASC 855-10, the Company has analyzed its operations from September 30, 2018 to October 30, 2018 and has determined that it has no material subsequent events to disclose in these financial statements.</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white"><u>NOTE 2 - GOING CONCERN</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">The financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.&#160; The Company has incurred losses since inception resulting in an accumulated deficit of $871,112 as of September 30, 2018 and further losses are anticipated in the development of its business raising substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of common stock.&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>NOTE 4 &#8211; LOANS PAYABLE</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the fiscal year ended March 31, 2016, the Company obtained a loan from a third party in the amount of $4,175. A further $9,990 was loaned to the Company in the six months ended September 30, 2016. This loan is non-interest bearing, is unsecured and has no fixed terms of repayment.</font></p> 560000 84374 47500 10000 5000 5000 <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Reclassifications</u></font></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the six month period September 30, 2018.</font></p> 4175 9990 20952 75 3067 20952 75 44638 78467 44638 78467 30000 45000 473 1354 14165 14165 17948 20952 75 -23686 -78392 -871112 -825818 267627 350693 432052 496733 47747 560000 26762638 15000 2500 5000 true false true 17885 75 150 7523 1147 135655 473 67182 244717 55238 63417 63417 44147 1698 20509 1383 -45294 170781 -20982 50090 -45294 170781 -20982 50090 34418928 31957000 92867280 31957000 -0.0013 0.0053 -0.0002 0.0016 -67190 -7373 124287 -244717 881 -11368 17948 5675 -3067 85000 15000 100000 17810 -7373 395529 23943 39373 332213 124287 252896 308135 55239 <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>NOTE 5 &#8211; LOAN ADVANCES</u></font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 10, 2018, the Company entered into a non-binding Memorandum of Understanding with Dr. Judy Pham wherein Dr. Pham agreed to provide up to $100,000 in equity financing to assist with a corporate reorganization including bringing the Company current in its regulatory filings. On September 26, 2018 Dr. Phan completed her commitment to advance the Company $100,000. On September 27, 2018, the Company entered into a Securities Purchase Agreement with Dr. Judy Pham whereby she acquired 422,222,670 common shares of the Company for the $100,000 in loan advances.</font></p> 100000 422222670 EX-101.SCH 7 atao-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENT OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - LOAN ADVANCES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - COMMON STOCK link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - LOAN ADVANCES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - COMMON STOCK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 atao-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 atao-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 atao-20180930_lab.xml XBRL LABEL FILE Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Amendment Description Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Is Entity Emerging Growth Company? Elected Not To Use the Extended Transition Period Entity Filer Category Entity Small Business Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Advances and deposits Total current assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable Loans payable Interest payable Promissory note due to related party Total current liabilities Total Liabilities Stockholders' Equity (Deficit) Common Stock, $0.001 par value, 2,000,000,000 shares authorized; 496,732,553 shares issued and outstanding at September 30, 2018 and 47,747,245 as at March 31, 2018 Additional paid-in capital Common Stock subscribed Accumulated deficit Total stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Expenses Total General and Administrative expenses Gain on conversion of debt Change in the fair value of derivative liabilities Interest expense Loss (earnings) before income taxes Income taxes Net loss (earnings) Loss (earnings) per share - Basic and Diluted Weighted Average Shares - Basic and Diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustment to reconcile net loss to net cash used in operating activities: Changes in Advances and deposits Changes in Accounts payable Changes in Interest payable Changes in Fair value of derivative liabilities Changes in Debt discount Cash Used In Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES Cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from common stock subscriptions Payments on Promissory Note due to related party Cash provided by financing activities NET INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS Beginning of period End of period Supplemental disclosures of cash flow information Taxes paid Interest paid Non-cash Financing and Investing Activities Conversion of Promissory Notes to Third Parties Conversion of Promissory Notes to Related Party Accrued Interest on Promissory Notes Conversion of and Accrued Interest on Promissory Notes, total Interest expense - debt discount in period Reduction of derivative liability in period Reduction of derivative liability - mark to market on conversion of Promissory Notes Reduction of derivative liability, total Accounting Policies [Abstract] ORGANIZATION AND BUSINESS OPERATIONS Organization, Consolidation and Presentation of Financial Statements [Abstract] GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Payables and Accruals [Abstract] LOANS PAYABLE Notes to Financial Statements LOAN ADVANCES Stockholders' Equity Note [Abstract] COMMON STOCK Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Cash and Cash Equivalents Basic and Diluted Income (Loss) Per Share Income Taxes Fair Value of Financial Instruments Use of Estimates Reclassifications Organization And Business Operations Cash advanced to CURE Write off of Sales and Distrubtion Licenses Accumulated losses Maximum amount insured on bank deposits Additional loan from third party Advances received pursuant to Securities Purchase Agreement Common stock issued pursuant to Securities Purchase Agreement, shares Common stock, shares issued and outstanding Common stock, shares issued and outstanding Promissory note conversions, shares issued Loans from Directors Partial repayment on new Promissory Note One time payment to officer upon signing of consulting agreement (1) Monthly payment to officer per consulting agreement (1) Additional payment for services provided (1) Amounts paid pursuant to contract (1) Agreement with sole officer and director of Company, monthly payment (2) Amounts paid pursuant to agreement (2) Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity GainLossConversionOfDebt Gain (Loss) on Derivative Instruments, Net, Pretax Income (Loss) from Continuing Operations before Income Taxes, Domestic Earnings Per Share, Basic and Diluted Increase (Decrease) in Accounts Payable Increase (Decrease) in Interest Payable, Net Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Repayments of Convertible Debt EX-101.PRE 11 atao-20180930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
6 Months Ended
Sep. 30, 2018
Oct. 30, 2018
Document And Entity Information    
Entity Registrant Name ALTAIR INTERNATIONAL CORP.  
Entity Central Index Key 0001570937  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --03-31  
Is Entity's Reporting Status Current? Yes  
Is Entity Emerging Growth Company? true  
Elected Not To Use the Extended Transition Period false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Common Stock, Shares Outstanding   496,732,553
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2019  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
BALANCE SHEETS (Unaudited) - USD ($)
Sep. 30, 2018
Mar. 31, 2018
Current Assets    
Cash $ 17,885 $ 75
Advances and deposits 3,067
Total current assets 20,952 75
Total assets 20,952 75
Current Liabilities    
Accounts payable 17,948
Loans payable 14,165 14,165
Interest payable 473 1,354
Promissory note due to related party 30,000 45,000
Total current liabilities 44,638 78,467
Total Liabilities 44,638 78,467
Stockholders' Equity (Deficit)    
Common Stock, $0.001 par value, 2,000,000,000 shares authorized; 496,732,553 shares issued and outstanding at September 30, 2018 and 47,747,245 as at March 31, 2018 496,733 47,747
Additional paid-in capital 350,693 432,052
Common Stock subscribed 267,627
Accumulated deficit (871,112) (825,818)
Total stockholders' equity (deficit) (23,686) (78,392)
Total liabilities and stockholders' equity (deficit) $ 20,952 $ 75
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2018
Mar. 31, 2018
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, authorized 2,000,000,000 75,000,000
Common stock, issued 496,732,553 47,747,245
Common stock, outstanding 496,732,553 47,747,245
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
STATEMENT OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Expenses        
Total General and Administrative expenses $ 20,509 $ 1,383 $ 44,147 $ 1,698
Gain on conversion of debt (63,417) (63,417)
Change in the fair value of derivative liabilities (55,238) (244,717)
Interest expense 473 67,182 1,147 135,655
Loss (earnings) before income taxes 20,982 (50,090) 45,294 (170,781)
Income taxes
Net loss (earnings) $ 20,982 $ (50,090) $ 45,294 $ (170,781)
Loss (earnings) per share - Basic and Diluted $ 0.0002 $ (0.0016) $ 0.0013 $ (0.0053)
Weighted Average Shares - Basic and Diluted 92,867,280 31,957,000 34,418,928 31,957,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ (45,294) $ 170,781
Adjustment to reconcile net loss to net cash used in operating activities:    
Changes in Advances and deposits (3,067)  
Changes in Accounts payable (17,948) (5,675)
Changes in Interest payable (881) 11,368
Changes in Fair value of derivative liabilities (244,717)
Gain on conversion of debt (63,417)
Changes in Debt discount 124,287
Cash Used In Operating Activities (67,190) (7,373)
CASH FLOWS FROM INVESTING ACTIVITIES    
Cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from common stock subscriptions 100,000
Payments on Promissory Note due to related party (15,000)
Cash provided by financing activities 85,000
NET INCREASE IN CASH AND CASH EQUIVALENTS 17,810 (7,373)
CASH AND CASH EQUIVALENTS    
Beginning of period 75 7,523
End of period 17,885 150
Supplemental disclosures of cash flow information    
Taxes paid
Interest paid
Non-cash Financing and Investing Activities    
Conversion of Promissory Notes to Third Parties 332,213
Conversion of Promissory Notes to Related Party 39,373
Accrued Interest on Promissory Notes 23,943
Conversion of and Accrued Interest on Promissory Notes, total 395,529
Interest expense - debt discount in period 124,287
Reduction of derivative liability in period 252,896
Reduction of derivative liability - mark to market on conversion of Promissory Notes 55,239
Reduction of derivative liability, total $ 308,135
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
ORGANIZATION AND BUSINESS OPERATIONS
6 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
ORGANIZATION AND BUSINESS OPERATIONS

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

 

Organization and Description of Business

 

ALTAIR INTERNATIONAL CORP. (the “Company”) was incorporated under the laws of the State of Nevada on December 20, 2012. The Company’s physical address is 18934 N 92nd Way, Scottsdale, AZ 85255. The Company is in the development stage as defined under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915-205 "Development-Stage Entities.”

 

The Company is currently engaged in identifying and assessing new business opportunities.

 

On November 11, 2014, the Company entered into a strategic alliance with Cure Pharmaceutical Corporation (“CURE”), a California company engaged in the development of oral thin film (“OTF”) for the delivery of nutraceutical, over-the-counter and prescription products. This alliance was initially comprised of an Exclusive License and Distribution Agreement for CURE’s Sildenafil Products in defined territories, a joint venture agreement for the procurement of equipment specific for oral thin film products and further joint ventures and other business relationships for the purpose of completing the development and marketing of additional products. Altair advanced $560,000 to CURE in this regard.

 

In September, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products. In its place, the Company and CURE entered into an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products. The Company has been unable to generate any sales of these products due to a lack of working capital and the human resources required to introduce the products to market. The Company wrote off its $560,000 investment in the agreement in the financial statements for the year ended March 31, 2017.

 

The Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described above.

 

Since inception (December 20, 2012) through September 30, 2018, the Company has not generated any revenue and has accumulated losses of $871,112.

 

In management’s opinion all adjustments necessary for a fair statement of the results for the interim periods have been made, and that all adjustments have been made to maintain the books in accordance with GAAP. Furthermore, sufficient disclosures have been made in order to ensure that the interim financial statements will not be misleading.

XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
GOING CONCERN
6 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 2 - GOING CONCERN

 

The financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.  The Company has incurred losses since inception resulting in an accumulated deficit of $871,112 as of September 30, 2018 and further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern.  The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of common stock. 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six month periods ending September 30, 2018 and 2017 and year ending March 31, 2018.

 

Cash and Cash Equivalents

 

For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At September 30, 2018 the Company's bank deposits did not exceed the insured amounts.

 

Basic and Diluted Income (Loss) Per Share

 

The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period.  Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.

 

Income Taxes

 

The Company follows the liability method of accounting for income taxes.  Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences).  The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Fair Value of Financial Instruments

 

FASB ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

 

These tiers include:

 

Level 1: defined as observable inputs such as quoted prices in active markets;

 

Level 2:  defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

Level 3:  defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Reclassifications

 

Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the six month period September 30, 2018.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
LOANS PAYABLE
6 Months Ended
Sep. 30, 2018
Payables and Accruals [Abstract]  
LOANS PAYABLE

NOTE 4 – LOANS PAYABLE

 

During the fiscal year ended March 31, 2016, the Company obtained a loan from a third party in the amount of $4,175. A further $9,990 was loaned to the Company in the six months ended September 30, 2016. This loan is non-interest bearing, is unsecured and has no fixed terms of repayment.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
LOAN ADVANCES
6 Months Ended
Sep. 30, 2018
Notes to Financial Statements  
LOAN ADVANCES

NOTE 5 – LOAN ADVANCES

 

On April 10, 2018, the Company entered into a non-binding Memorandum of Understanding with Dr. Judy Pham wherein Dr. Pham agreed to provide up to $100,000 in equity financing to assist with a corporate reorganization including bringing the Company current in its regulatory filings. On September 26, 2018 Dr. Phan completed her commitment to advance the Company $100,000. On September 27, 2018, the Company entered into a Securities Purchase Agreement with Dr. Judy Pham whereby she acquired 422,222,670 common shares of the Company for the $100,000 in loan advances.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMON STOCK
6 Months Ended
Sep. 30, 2018
Stockholders' Equity Note [Abstract]  
COMMON STOCK

NOTE 6 – COMMON STOCK

 

On August 24, 2018, the Company increased its authorized share capital from 75,000,000 common shares to 2,000,000 common shares with a par value of $0.001.

 

The Company had 47,747,245 common shares issued and outstanding at March 31, 2018.

 

In addition, the Company had received share subscriptions and Promissory Note conversion notices for the issuance of an additional 26,762,638 common shares. These shares were issued to the subscribers on April 19, 2018.

 

On September 27, 2018, the Company entered into a Securities Purchase Agreement with Dr. Judy Pham whereby she acquired 422,222,670 common shares of the Company for $100,000 in cash advances.

 

The Company had 496,732,553 common shares issued and outstanding at September 30, 2018.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
RELATED PARTY TRANSACTIONS
6 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

 

From inception through September 29, 2016, the Directors loaned the Company $84,374 net of repayments to pay for incorporation costs, general and administrative expenses and professional fees and the acquisition of sales and distribution licenses and advances to Cure Pharmaceutical.  On September 29, 2016, this amount was settled through the issuance of a convertible promissory note. On September 29, 2017, the Director converted $39,373 of principal and $5,062 accrued interest on the promissory note into 4,443,565 shares of common stock. A new non-convertible unsecured, 6% promissory note for the remaining principal balance of $45,000 was issued. The new note matures in eighteen months. On September 29, 2018, the Company made a partial repayment of $15,000 on this note.

 

On September 29, 2016, the Company entered into a consulting agreement with the Company’s sole officer and director for the provision of management and financial services. This agreement called for a one time payment of $10,000 on signing of the agreement, and payments of $5,000 per month for six months, terminating on March 30, 2017. In addition, an amount of $5,000 for services provided in September, 2016 was payable on either the termination of the contract or completion of a minimum $500,000 financing. As of September 30, 2018, all amounts due to the consultant including $2,500 in late payment fees pursuant to this contract ($47,500) had been paid.

 

On April 10, 2018, the Company agreed to pay the sole officer and director of the company $2,500 per month for a period of 4 months for the provision of management and financial services. On September 1, 2018, the Company agreed to extend this contract on a month-to-month basis at the existing rate of $2,500 per month. $12,500 has been paid to September 30, 2018 pursuant to this agreement.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUBSEQUENT EVENTS
6 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 8 – SUBSEQUENT EVENTS

 

In accordance with ASC 855-10, the Company has analyzed its operations from September 30, 2018 to October 30, 2018 and has determined that it has no material subsequent events to disclose in these financial statements.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six month periods ending September 30, 2018 and 2017 and year ending March 31, 2018.

Cash and Cash Equivalents

Cash and Cash Equivalents

 

For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At September 30, 2018 the Company's bank deposits did not exceed the insured amounts.

Basic and Diluted Income (Loss) Per Share

Basic and Diluted Income (Loss) Per Share

 

The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period.  Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.

Income Taxes

Income Taxes

 

The Company follows the liability method of accounting for income taxes.  Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences).  The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

FASB ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

 

These tiers include:

 

Level 1: defined as observable inputs such as quoted prices in active markets;

 

Level 2:  defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

Level 3:  defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Reclassifications

Reclassifications

 

Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the six month period September 30, 2018.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) - USD ($)
12 Months Ended
Mar. 31, 2017
Mar. 31, 2015
Sep. 30, 2018
Mar. 31, 2018
Organization And Business Operations        
Cash advanced to CURE   $ 560,000    
Write off of Sales and Distrubtion Licenses $ 560,000      
Accumulated losses     $ (871,112) $ (825,818)
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
GOING CONCERN (Details Narrative) - USD ($)
Sep. 30, 2018
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ (871,112) $ (825,818)
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
Sep. 30, 2018
USD ($)
Accounting Policies [Abstract]  
Maximum amount insured on bank deposits $ 250,000
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
LOANS PAYABLE (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended
Sep. 30, 2016
Mar. 31, 2016
Payables and Accruals [Abstract]    
Additional loan from third party $ 9,990 $ 4,175
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
LOAN ADVANCES (Details Narrative)
6 Months Ended
Sep. 30, 2018
USD ($)
shares
Notes to Financial Statements  
Advances received pursuant to Securities Purchase Agreement | $ $ 100,000
Common stock issued pursuant to Securities Purchase Agreement, shares | shares 422,222,670
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMON STOCK (Details Narrative) - USD ($)
6 Months Ended
Sep. 30, 2018
Mar. 31, 2018
Stockholders' Equity Note [Abstract]    
Common stock, authorized 2,000,000,000 75,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares issued and outstanding 496,732,553 47,747,245
Common stock, shares issued and outstanding 496,732,553 47,747,245
Promissory note conversions, shares issued 26,762,638  
Advances received pursuant to Securities Purchase Agreement $ 100,000  
Common stock issued pursuant to Securities Purchase Agreement, shares 422,222,670  
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 45 Months Ended
Sep. 30, 2016
Sep. 30, 2018
Mar. 30, 2017
Sep. 29, 2016
Related Party Transactions [Abstract]        
Loans from Directors       $ 84,374
Partial repayment on new Promissory Note   $ (15,000)    
One time payment to officer upon signing of consulting agreement (1)       $ 10,000
Monthly payment to officer per consulting agreement (1)     $ 5,000  
Additional payment for services provided (1) $ 5,000      
Amounts paid pursuant to contract (1)   47,500    
Agreement with sole officer and director of Company, monthly payment (2)   2,500    
Amounts paid pursuant to agreement (2)   $ 5,000    
EXCEL 33 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 34 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 17 94 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://ATAO/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS (Unaudited) Sheet http://ATAO/role/BalanceSheets BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://ATAO/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENT OF OPERATIONS (Unaudited) Sheet http://ATAO/role/StatementOfOperations STATEMENT OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://ATAO/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS Sheet http://ATAO/role/OrganizationAndBusinessOperations ORGANIZATION AND BUSINESS OPERATIONS Notes 6 false false R7.htm 00000007 - Disclosure - GOING CONCERN Sheet http://ATAO/role/GoingConcern GOING CONCERN Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://ATAO/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - LOANS PAYABLE Sheet http://ATAO/role/LoansPayable LOANS PAYABLE Notes 9 false false R10.htm 00000010 - Disclosure - LOAN ADVANCES Sheet http://ATAO/role/LoanAdvances LOAN ADVANCES Notes 10 false false R11.htm 00000011 - Disclosure - COMMON STOCK Sheet http://ATAO/role/CommonStock COMMON STOCK Notes 11 false false R12.htm 00000012 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://ATAO/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 12 false false R13.htm 00000013 - Disclosure - SUBSEQUENT EVENTS Sheet http://ATAO/role/SubsequentEvents SUBSEQUENT EVENTS Notes 13 false false R14.htm 00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://ATAO/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 00000015 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) Sheet http://ATAO/role/OrganizationAndBusinessOperationsDetailsNarrative ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) Details http://ATAO/role/OrganizationAndBusinessOperations 15 false false R16.htm 00000016 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://ATAO/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://ATAO/role/GoingConcern 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://ATAO/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://ATAO/role/SummaryOfSignificantAccountingPoliciesPolicies 17 false false R18.htm 00000018 - Disclosure - LOANS PAYABLE (Details Narrative) Sheet http://ATAO/role/LoansPayableDetailsNarrative LOANS PAYABLE (Details Narrative) Details http://ATAO/role/LoansPayable 18 false false R19.htm 00000019 - Disclosure - LOAN ADVANCES (Details Narrative) Sheet http://ATAO/role/LoanAdvancesDetailsNarrative LOAN ADVANCES (Details Narrative) Details http://ATAO/role/LoanAdvances 19 false false R20.htm 00000020 - Disclosure - COMMON STOCK (Details Narrative) Sheet http://ATAO/role/CommonStockDetailsNarrative COMMON STOCK (Details Narrative) Details http://ATAO/role/CommonStock 20 false false R21.htm 00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://ATAO/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://ATAO/role/RelatedPartyTransactions 21 false false All Reports Book All Reports atao-20180930.xml atao-20180930.xsd atao-20180930_cal.xml atao-20180930_def.xml atao-20180930_lab.xml atao-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 39 0001554795-18-000310-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001554795-18-000310-xbrl.zip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�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end